Mounjaro, Wegovy, Foundayo and oral Wegovy: how to use them safely
How each weight-loss medication is taken, what side effects to expect, and why medical supervision prevents complications rather than just treating them.
Four medications now dominate obesity treatment, and patients often arrive having already bought one without knowing how to use it. Here is how each works, and why the doctor matters more than the drug.
The four options
Mounjaro (tirzepatide) — a weekly injection acting on two hormone receptors, GLP-1 and GIP. It produces the largest average weight loss of the approved injectables, around 20%.
Wegovy (semaglutide) — a weekly injection acting on GLP-1 alone, with around 15% average weight loss and the longest safety record in this group.
Wegovy pill (oral semaglutide 25 mg) — the first GLP-1 tablet approved for weight loss, taken once daily. It must be taken on waking, on an empty stomach, with no more than a small sip of water, and nothing else by mouth for 30 minutes. Trial weight loss was around 16.6%.
Foundayo (orforglipron) — a once-daily pill approved in April 2026. Unlike oral Wegovy it can be taken at any time of day, with or without food or water, which suits many patients' routines better. Average weight loss was around 12.4% in the pivotal trial.
How they are actually used
All four start at a low dose and increase gradually over months. This is not caution for its own sake: escalating too quickly is the main cause of severe nausea and vomiting, and the main reason people abandon treatment. Injections are given into the abdomen, thigh or upper arm, rotating the site each week, and can be taken at any time of day with or without food.
What to expect
Nausea, constipation, diarrhoea, bloating and reflux are common early and when the dose rises. They usually settle. Smaller meals, less fatty food, adequate water and slower dose escalation control most of it.
Uncommon but serious problems include pancreatitis, gallstones (the rapid weight loss itself causes them), dehydration and, in people with diabetes on insulin or sulfonylureas, low blood sugar. These need recognising early — which is the entire argument for supervision.
Why a doctor genuinely matters here
This is the part patients underestimate. Before prescribing, a doctor screens for the conditions that make these medications unsafe — a personal or family history of medullary thyroid cancer, previous pancreatitis, severe gastroparesis, pregnancy or planning pregnancy. Someone buying online skips that check entirely.
During treatment, supervision means the dose is matched to your tolerance rather than a schedule, side effects are managed before they force you to quit, your muscle mass is protected with adequate protein and resistance training, and your other medications — insulin, blood pressure tablets — are adjusted as your weight falls. Left unmanaged, a patient can lose weight and still end up weaker, deficient in vitamins, or in hospital with pancreatitis that was dismissed as indigestion.
Then there is the question everyone forgets to ask: what happens when you stop. Appetite returns, and most of the weight follows within a year unless a maintenance plan exists. That plan is a medical decision, not a pharmacy one.
Finally, avoid any product sold outside a licensed pharmacy. Counterfeit weight-loss injections have repeatedly been found to contain wrong doses, contamination, or entirely different substances.
This article is educational and does not replace personalized medical advice. To discuss which option suits you, contact Professor Jamal's clinic on WhatsApp +965 60621662 or Kuwait Hospital +965 22207777.
Related articles
Bimagrumab: the muscle-preserving partner that could change obesity treatment
In the phase 2b BELIEVE trial, bimagrumab plus semaglutide produced 22.1% weight loss with 92.8% of it from fat — and lean-mass loss limited to 2.9%.
Apitegromab: could it preserve muscle during tirzepatide weight loss?
The phase 2 EMBRAZE trial tested an investigational myostatin inhibitor alongside tirzepatide. It reduced lean-mass loss by 1.9 kg without changing total weight loss.
The future of weight-loss drugs: can we lose fat without losing muscle?
Obesity medicine is shifting from how much weight was lost to what kind of tissue was lost. An overview of the emerging fat-loss plus muscle-preservation strategy.
Have questions about your own health?
Ask the AI Knowledge Center — trained on Professor Jamal's own publications and guidelines — or book a consultation in person.